ArchiMed-backed Clean Biologics appoints CEO

Clean Biologics, which is backed by ArchiMed, has named Joseph Jammal as CEO.

Clean Biologics, which is backed by ArchiMed, has named Joseph Jammal as CEO. Prior to becoming Clean Biologics’ CEO, Jammal was president and CEO of Cisbio Bioassays. Clean Biologics specializes in viral vector-based vaccines like those used to combat COVID-19.

PRESS RELEASE

February 23, 2021 – Clean Biologics announces the appointment of Joseph Jammal as Chief Executive Officer. He succeeds Olivier Boisteau, the co-founder of the group, who remains a key Strategic Advisor and Board Member.

Clean Biologics is a bioindustry outsourcing group, known as a contract development and management organization. With a long history of innovation and rapid growth, Clean Biologics’ expansion accelerated substantially in 2018, when European and U.S. private equity healthcare specialist ArchiMed took a majority stake in the firm, partnering with owners and management and backing their plans with financial and strategic support.

“I am very proud of what we’ve accomplished so far,” says Olivier Boisteau. “I look forward to this new chapter and I am confident that Joseph Jammal is the right leader to successfully drive the operational development of our rapidly growing group.”

Specialized in biosafety testing, cell bank and virus seed stock production & storage for third parties, Clean Biologics complemented its focus on the production and vetting of the building blocks of drugs and vaccines with the acquisition and integration of Naobios in 2019. Naobios is a CDMO specialized in the manufacture of viral vector-based vaccines – like those being used to combat COVID-19 – and oncolytic viruses, which preferentially infect and kill cancer cells. With Naobios, Clean Biologics is now one of the only CDMOs in the world with a full range of services for vaccine and drug production based on so-called starting materials.

Joseph brings strong international experience and in-depth knowledge of the In Vitro Diagnostics and Life Science fields to the expanded group. Prior to becoming Clean Biologics’ CEO, Joseph served as President & CEO of Cisbio Bioassays, an international developer and manufacturer of products and technologies used for in vitro diagnostics and drug discovery. Joseph transformed Cisbio by focusing on its most profitable and promising businesses, while reinforcing its research and development. His actions led to double-digit annual growth in Cisbio’s Life Sciences business, a turnaround in the company’s U.S. operations and a renewed emphasis on innovation.

Previously, Joseph worked in a range of senior positions (over more than 15 years) at bioMérieux, one of the world’s largest developers and manufacturers of diagnostic products. While there, he served as Worldwide Vice-President in charge of Commercial Operations and Customer Service for the Life Science Business Unit, reorganizing and improving the performance of sales, marketing and customer service. He also led bioMérieux’s Food Diagnostics Business, successfully achieving his cross-border objectives in an international, matrix-based environment.

“I am very excited to get this chance to reinforce the talented team at Clean Biologics,” says Joseph Jammal. “There’s a huge opportunity to further grow and develop the company internationally, while always better serving our customers.”
About Clean Biologics – Founded in 2000, Clean Biologics (formerly known as Clean Cells) is one of the only contract development and management organizations in the Biopharma sector offering comprehensive, end-to-end services. Its services for pharma companies and research organizations include GMP-grade production and secure storage of cell and virus banks; viral and biological safety testing of biopharmaceuticals, including recombinant proteins, therapeutic antibodies, vaccines, cell and gene therapies, and phage therapy. It also offers GMP-compliant production services for cell therapy products based on viral vectors – like those being used to combat COVID-19 – and oncolytic viruses, which preferentially infect and kill cancer cells. Clean Biologics, based near Nantes, France, sells its products and services throughout the world. Clean Biologics’ enduring ambition is to help improve healthcare by playing a major role in the development of revolutionary therapies.